Terumo Corporation
DB:TUO Voorraadrapport
Marktkapitalisatie: €27.3b
Terumo Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6 Terumo heeft een totaal eigen vermogen van ¥1,313.5B en een totale schuld van ¥174.8B, wat de schuld-eigenvermogensverhouding op 13.3% brengt. De totale activa en totale passiva bedragen respectievelijk ¥1,752.3B en ¥438.8B. De EBIT Terumo is ¥161.8B waardoor de rentedekking 88.8 is. Het heeft contanten en kortetermijnbeleggingen van ¥194.9B.
Belangrijke informatie
13.3%
Verhouding schuld/eigen vermogen
Rente dekkingsratio 88.8x Contant JP¥194.92b Aandelen JP¥1.31t Totaal verplichtingen JP¥438.75b Totaal activa JP¥1.75t
Recente financiële gezondheidsupdates
Toon alle updates
Second quarter 2025 earnings released: EPS: JP¥19.74 (vs JP¥18.49 in 2Q 2024) Nov 09
Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024 Sep 25
Upcoming dividend of JP¥13.00 per share Sep 20 Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million. Aug 30
First quarter 2025 earnings released: EPS: JP¥22.82 (vs JP¥15.14 in 1Q 2024) Aug 09
Final dividend of JP¥13.00 announced Jul 11
Full year 2024 earnings released: EPS: JP¥71.50 (vs JP¥59.50 in FY 2023) Jul 05
Less than half of directors are independent Jul 02
Now 21% overvalued Jun 05
Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024 Jun 02
Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System May 29
Full year 2024 earnings released: EPS: JP¥71.50 (vs JP¥59.50 in FY 2023) May 16
Upcoming dividend of JP¥22.00 per share Mar 21
Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024 Mar 17
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Feb 09
Third quarter 2024 earnings released: EPS: JP¥40.06 (vs JP¥39.97 in 3Q 2023) Feb 08
Now 28% overvalued after recent price rise Feb 08 Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024
Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024 Dec 03
Second quarter 2024 earnings released: EPS: JP¥36.99 (vs JP¥23.75 in 2Q 2023) Nov 17
Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023 Oct 01
Upcoming dividend of JP¥22.00 per share at 1.1% yield Sep 21
Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million. Aug 10
First quarter 2024 earnings released: EPS: JP¥30.28 (vs JP¥29.61 in 1Q 2023) Aug 10
Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023 Jun 21 Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
Full year 2023 earnings released: EPS: JP¥119 (vs JP¥117 in FY 2022) May 16
Terumo Corporation, Annual General Meeting, Jun 27, 2023 May 16
Upcoming dividend of JP¥21.00 per share at 1.2% yield Mar 23
Third quarter 2023 earnings released: EPS: JP¥39.97 (vs JP¥28.70 in 3Q 2022) Feb 10 Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
Second quarter 2023 earnings released: EPS: JP¥23.75 (vs JP¥29.22 in 2Q 2022) Nov 16
Less than half of directors are independent Nov 16
Second quarter 2023 earnings released: EPS: JP¥23.75 (vs JP¥29.22 in 2Q 2022) Nov 12 Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023 Nov 10
Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022 Sep 28
Upcoming dividend of JP¥18.00 per share Sep 22
Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543). Sep 09
NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation. Sep 08
First quarter 2023 earnings released: EPS: JP¥29.61 (vs JP¥36.90 in 1Q 2022) Aug 10 Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023
Less than half of directors are independent Jul 05
Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan May 16
Full year 2022 earnings released: EPS: JP¥117 (vs JP¥102 in FY 2021) May 14 Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.
Less than half of directors are independent Apr 27
Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022 Apr 08
Upcoming dividend of JP¥16.00 per share Mar 23
Upcoming dividend of JP¥16.00 per share Mar 23
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 10
Terumo Corporation, Annual General Meeting, Jun 22, 2022 Feb 10 Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022
Second quarter 2022 earnings released: EPS JP¥29.22 (vs JP¥23.63 in 2Q 2021) Nov 05
Upcoming dividend of JP¥15.00 per share Sep 22
First quarter 2022 earnings released: EPS JP¥36.90 (vs JP¥18.57 in 1Q 2021) Aug 05
Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020) Jun 28
Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020) May 14 Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022
Upcoming dividend of JP¥14.00 per share Mar 23
Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc. Feb 25
New 90-day high: €36.40 Feb 20
Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd Feb 08
Third quarter 2021 earnings released: EPS JP¥35.40 (vs JP¥28.22 in 3Q 2020) Feb 06
Revenue beats expectations Feb 06
Terumo Corporation Revises Earnings Guidance for the Fourth Quarter of Fiscal 2021 Feb 06
IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand Jan 06
Terumo Corporation to Report Q3, 2021 Results on Feb 04, 2021 Dec 23
Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for Dblg1 Automated Insulin Delivery Solution in Japanese Market Nov 17
New 90-day high: €36.00 Nov 16
Revenue beats expectations Nov 07
Second quarter 2021 earnings released: EPS JP¥23.64 Nov 07
New 90-day low: €31.00 Oct 21
IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million Oct 06
Terumo Corporation to Report Q2, 2021 Results on Nov 05, 2020 Sep 27
New 90-day high - €35.40 Sep 09
Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc. Aug 25
Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million. Jul 30
Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020 Jun 29
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ¥679.2B ) TUO } overtreffen de korte termijn passiva ( ¥231.0B ).
Langlopende schulden: De kortetermijnactiva TUO ( ¥679.2B ) overtreffen de langetermijnschulden ( ¥207.7B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: TUO heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van TUO is de afgelopen 5 jaar gedaald van 29.5% naar 13.3%.
Schuldendekking: De schuld van TUO wordt goed gedekt door de operationele kasstroom ( 110.8% ).
Rentedekking: De rentebetalingen op de schuld van TUO worden goed gedekt door EBIT ( 88.8 x dekking).
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}